cll1 and cd38 dual-target car-t injection
Cell therapyexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 10, 2023 (NCT06110208)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Lymphocyte differentiation antigen CD38Immunity, passive
CD38 immunity, passive
- C-type lectin domain family 12 member AImmunity, passive
immunity, passive - cll1
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06880354 | Phase 1 | May 22, 2025 | AstraZeneca, China Academy of Chinese Medical Sciences, Gracell Biotechnology Ltd. |
| NCT06110208 | Early Phase 1 (Phase 1) | Oct 10, 2023 | Gracell Biotechnology Ltd., People's Liberation Army of China |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gracell Biotechnology Ltd. | For profit | 2 | 0 | 1 | 2023 |
| AstraZeneca | For profit | 1 | 0 | 1 | 2025 |
| China Academy of Chinese Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2025 |
| People's Liberation Army of China | Government | 1 | 1 | 1 | 2023 |
4 organizations
Page 1 / 1